HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tadahiro Shoji Selected Research

Therapeutics

1/2022Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023.
1/2022Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
12/2021Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.
5/2021Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer.
11/2020Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2].
3/2020Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
3/2020A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy.
10/2019A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
9/2019Immunotherapy for Uterine Cervical Cancer.
1/2018Gemcitabine and docetaxel in a patient with primary ovarian leiomyosarcoma: a case report and review of literature.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tadahiro Shoji Research Topics

Disease

26Neoplasms (Cancer)
01/2022 - 06/2008
16Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 06/2008
13Uterine Cervical Neoplasms (Cancer of the Cervix)
01/2022 - 04/2010
7Carcinoma (Carcinomatosis)
12/2021 - 06/2008
7Squamous Cell Carcinoma (Epidermoid Carcinoma)
07/2021 - 06/2008
6Disease Progression
01/2022 - 10/2012
3Ovarian Epithelial Carcinoma
09/2019 - 12/2011
3Neutropenia
01/2018 - 08/2013
3Ascites
07/2014 - 06/2008
2Fistula
01/2022 - 08/2018
2Mucinous Adenocarcinoma (Mucinous Carcinoma)
12/2021 - 02/2014
2Lung Neoplasms (Lung Cancer)
11/2020 - 09/2019
2Hypertension (High Blood Pressure)
08/2018 - 01/2018
2Neoplasm Metastasis (Metastasis)
08/2018 - 01/2018
2Carcinosarcoma
06/2015 - 12/2014
2Lymphatic Metastasis
04/2015 - 06/2008
2Anemia
08/2013 - 12/2011
2Endometrial Neoplasms (Endometrial Cancer)
01/2012 - 11/2007
1Hypoxia (Hypoxemia)
11/2020
1Signet Ring Cell Carcinoma
03/2020
1Colorectal Neoplasms (Colorectal Cancer)
09/2019
1Thrombosis (Thrombus)
08/2018
1Proteinuria
08/2018
1Intestinal Perforation
08/2018
1Dyspnea (Shortness of Breath)
01/2018
1Interstitial Lung Diseases (Interstitial Lung Disease)
01/2018
1Leiomyosarcoma
01/2018
1Surgical Blood Loss
12/2016
1Nausea
03/2015
1Vomiting
03/2015
1Sarcoma (Soft Tissue Sarcoma)
12/2014
1Adenocarcinoma
04/2014
1Fatigue
08/2013
1Diarrhea
08/2013
1Thrombocytopenia (Thrombopenia)
08/2013
1Constipation
10/2012
1Carcinoid Tumor (Carcinoid)
10/2012
1Takotsubo Cardiomyopathy
01/2012

Drug/Important Bio-Agent (IBA)

14Carboplatin (JM8)FDA LinkGeneric
01/2022 - 11/2010
10Paclitaxel (Taxol)FDA LinkGeneric
01/2022 - 12/2011
10PlatinumIBA
01/2022 - 01/2011
9Irinotecan (Camptosar)FDA LinkGeneric
08/2017 - 04/2010
7Bevacizumab (Avastin)FDA Link
01/2022 - 01/2015
7taxaneIBA
10/2019 - 06/2008
4Docetaxel (Taxotere)FDA Link
07/2021 - 11/2010
4Cisplatin (Platino)FDA LinkGeneric
08/2016 - 04/2010
3liposomal doxorubicin (Doxil)FDA Link
10/2019 - 05/2014
3GemcitabineFDA Link
10/2019 - 01/2013
3nedaplatinIBA
08/2016 - 06/2008
3Proteins (Proteins, Gene)FDA Link
10/2015 - 06/2008
2AntigensIBA
01/2022 - 07/2016
2Angiogenesis InhibitorsIBA
03/2020 - 09/2019
21-dodecylpyridoxal (PLD)IBA
08/2017 - 05/2014
2squamous cell carcinoma-related antigenIBA
07/2016 - 04/2015
2Antineoplastic Agents (Antineoplastics)IBA
01/2013 - 06/2012
1niraparibIBA
05/2021
1olaparibIBA
05/2021
1Peptides (Polypeptides)IBA
11/2020
1EpitopesIBA
11/2020
1Neoplasm Antigens (Tumor Antigens)IBA
11/2020
1Growth Factor ReceptorsIBA
11/2020
1Immune Checkpoint InhibitorsIBA
03/2020
1Tumor Biomarkers (Tumor Markers)IBA
03/2020
14-boronic acid benzophenoneIBA
09/2019
1pazopanibFDA Link
01/2018
1veliparibIBA
11/2017
1GadoliniumIBA
09/2017
1VimentinIBA
09/2017
1Estrogen ReceptorsIBA
09/2017
1Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA
09/2017
1DesminIBA
09/2017
1Progesterone Receptors (Progesterone Receptor)IBA
09/2017
1Carcinoembryonic AntigenIBA
07/2016
1Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
05/2015
1Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA
05/2015
1Dexamethasone (Maxidex)FDA LinkGeneric
03/2015
1Palonosetron (Aloxi)FDA Link
03/2015
1AntiemeticsIBA
03/2015
1Triamcinolone Acetonide (Azmacort)FDA LinkGeneric
07/2014
1Dihydrotachysterol (AT 10)IBA
07/2014
1Oxaliplatin (Eloxatin)FDA LinkGeneric
04/2014
1EverolimusFDA Link
01/2014
1TOR Serine-Threonine KinasesIBA
01/2014
1Peptide YYIBA
10/2012
12- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA
01/2012

Therapy/Procedure

21Therapeutics
01/2022 - 11/2010
15Drug Therapy (Chemotherapy)
01/2022 - 12/2011
7Hysterectomy
03/2020 - 02/2014
7Neoadjuvant Therapy
12/2016 - 04/2010
4Chemoradiotherapy
05/2021 - 06/2008
3Radiotherapy
01/2022 - 06/2008
3Immunotherapy
11/2020 - 09/2019
2Salpingo-oophorectomy
03/2020 - 12/2014
2Combination Drug Therapy (Combination Chemotherapy)
08/2018 - 01/2011
1Adjuvant Chemotherapy
05/2021
1TP protocol
08/2018
1Brachytherapy
08/2018
1Radiofrequency Therapy
01/2018
1Operative Time
12/2016
1Drug Tapering
05/2014